
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10758946/publications.pdf Version: 2024-02-01



LEE M IMPOL

#	Article	lF	CITATIONS
1	Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. New England Journal of Medicine, 2015, 372, 1193-1203.	13.9	1,255
2	Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. Ophthalmology, 2016, 123, 1351-1359.	2.5	731
3	Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy. JAMA - Journal of the American Medical Association, 2015, 314, 2137.	3.8	599
4	Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results. Ophthalmology, 2015, 122, 375-381.	2.5	421
5	The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. Ophthalmology, 2002, 109, 2197-2206.	2.5	327
6	Nonsteroidal Anti-inflammatory Drugs inÂOphthalmology. Survey of Ophthalmology, 2010, 55, 108-133.	1.7	300
7	Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy. JAMA Ophthalmology, 2018, 136, 1138.	1.4	264
8	Quantifying Microvascular Abnormalities With Increasing Severity of Diabetic Retinopathy Using Optical Coherence Tomography Angiography. , 2017, 58, BIO307.		263
9	Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment. JAMA Ophthalmology, 2018, 136, 257.	1.4	218
10	Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity. JAMA - Journal of the American Medical Association, 2019, 321, 1880.	3.8	184
11	White spot syndromes of the retina: a hypothesis based on the common genetic hypothesis of autoimmune/inflammatory disease. American Journal of Ophthalmology, 2003, 135, 376-379.	1.7	182
12	Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema. JAMA Ophthalmology, 2018, 136, 29.	1.4	181
13	Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment. JAMA Ophthalmology, 2016, 134, 278.	1.4	159
14	Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment. JAMA Ophthalmology, 2016, 134, 888.	1.4	152
15	Improvement in Visual Acuity in Chronic Aphakic and Pseudophakic Cystoid Macular Edema After Treatment With Topical 0.5% Ketorolac Tromethamine. American Journal of Ophthalmology, 1991, 112, 514-519.	1.7	149
16	Aspirin Prevents the Disruption of the Blood–Aqueous Barrier in the Rabbit Eye. Nature, 1972, 238, 158-159.	13.7	135
17	Change in Diabetic Retinopathy Through 2 Years. JAMA Ophthalmology, 2017, 135, 558.	1.4	135
18	Acute Zonal Occult Outer Retinopathy. JAMA Ophthalmology, 2014, 132, 1089.	1.4	126

#	Article	IF	CITATIONS
19	Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging With Ultrawide-Field Imaging for Determining Severity of Diabetic Retinopathy. JAMA Ophthalmology, 2019, 137, 65.	1.4	125
20	Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema. American Journal of Ophthalmology, 2016, 164, 57-68.	1.7	123
21	Evaluation and Care of Patients with Diabetic Retinopathy. New England Journal of Medicine, 2020, 382, 1629-1637.	13.9	118
22	Prophylaxis of Pseudophakic Cystoid Macular Edema with Topical Indomethacin. Ophthalmology, 1982, 89, 885-890.	2.5	113
23	Association of Diabetic Macular Nonperfusion With Outer Retinal Disruption on Optical Coherence Tomography. JAMA Ophthalmology, 2015, 133, 1036.	1.4	105
24	PERIPAPILLARY PACHYCHOROID SYNDROME. Retina, 2018, 38, 1652-1667.	1.0	104
25	Effect of an Ultraviolet-filtering Intraocular Lens on Cystoid Macular Edema. Ophthalmology, 1985, 92, 366-369.	2.5	102
26	Importance of Considering the Middle Capillary Plexus on OCT Angiography in Diabetic Retinopathy. , 2018, 59, 2167.		97
27	PHARMACOLOGIC THERAPY OF PSEUDOPHAKIC CYSTOID MACULAR EDEMA. Retina, 2011, 31, 4-12.	1.0	96
28	Ocular Clinical Findings and Basement Membrane Changes in Goodpasture's Syndrome. American Journal of Ophthalmology, 1975, 79, 452-463.	1.7	87
29	Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol TÂExtension Study). Ophthalmology, 2020, 127, 1201-1210.	2.5	87
30	Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab. JAMA Ophthalmology, 2019, 137, 977.	1.4	85
31	En Face Optical Coherence Tomography Analysis to Assess the Spectrum of Perivenular Ischemia and Paracentral Acute Middle Maculopathy in Retinal Vein Occlusion. American Journal of Ophthalmology, 2017, 177, 131-138.	1.7	84
32	Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy. JAMA Ophthalmology, 2021, 139, 701.	1.4	81
33	Rationale and Application of the Protocol S Anti–Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy. Ophthalmology, 2019, 126, 87-95.	2.5	79
34	Early Response to Anti–Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T. American Journal of Ophthalmology, 2018, 195, 93-100.	1.7	77
35	Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti–Vascular Endothelial Growth Factor Therapy. JAMA Ophthalmology, 2019, 137, 382.	1.4	76
36	Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab. Ophthalmology, 2017, 124, 431-439.	2.5	74

#	Article	IF	CITATIONS
37	TOPICAL NEPAFENEC IN EYES WITH NONCENTRAL DIABETIC MACULAR EDEMA. Retina, 2015, 35, 944-956.	1.0	73
38	New associations of classic acute macular neuroretinopathy. British Journal of Ophthalmology, 2016, 100, 389-394.	2.1	73
39	Statistical Model of Optical Coherence Tomography Angiography Parameters That Correlate With Severity of Diabetic Retinopathy. , 2018, 59, 4292.		72
40	Pharmacologic Therapy of Aphakic Cystoid Macular Edema. Ophthalmology, 1982, 89, 891-897.	2.5	71
41	Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy. JAMA - Journal of the American Medical Association, 2020, 324, 2383.	3.8	70
42	Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. JAMA Ophthalmology, 2016, 134, 127.	1.4	68
43	Repeated Intravitreous Ranibizumab Injections for Diabetic Macular Edema and the Risk of Sustained Elevation of Intraocular Pressure or the Need for Ocular Hypotensive Treatment. JAMA Ophthalmology, 2015, 133, 589.	1.4	65
44	Differentiation of Diabetic Macular Edema From Pseudophakic Cystoid Macular Edema by Spectral-Domain Optical Coherence Tomography. , 2015, 56, 6724.		61
45	Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy. JAMA Ophthalmology, 2017, 135, 576.	1.4	59
46	Bullous Variant of Central Serous Chorioretinopathy. Ophthalmology, 2016, 123, 1541-1552.	2.5	56
47	Zika Virus Infection and the Eye. JAMA Ophthalmology, 2016, 134, 535.	1.4	56
48	Does Laser Still Have a Role in the Management of Retinal Vascular and Neovascular Diseases?. American Journal of Ophthalmology, 2011, 152, 332-339.e1.	1.7	55
49	The Bacillary Detachment in Posterior Segment Ocular Diseases. Ophthalmology Retina, 2020, 4, 454-456.	1.2	55
50	Pharmacologic Therapy of Aphakic and Pseudophakic Cystoid Macular Edema. Ophthalmology, 1985, 92, 807-810.	2.5	54
51	The Diabetic Retinopathy Clinical Research Network (DRCR.net) and Its Contributions to the Treatment of Diabetic Retinopathy. Ophthalmic Research, 2019, 62, 225-230.	1.0	54
52	Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning. JAMA Ophthalmology, 2020, 138, 945.	1.4	49
53	Vertical Hyperreflective Lesions on Optical Coherence Tomography in Vitreoretinal Lymphoma. JAMA Ophthalmology, 2019, 137, 194.	1.4	47
54	Anti–Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema. JAMA Ophthalmology, 2016, 134, 1429.	1.4	44

#	Article	IF	CITATIONS
55	Chorioretinal Lesions in a Case of Melanoma-Associated Retinopathy Treated With Pembrolizumab. JAMA Ophthalmology, 2016, 134, 1184.	1.4	43
56	Revolution to a New Standard Treatment of Diabetic Macular Edema. JAMA - Journal of the American Medical Association, 2014, 311, 2269.	3.8	40
57	Correlation of Central Retinal Thickness and Visual Acuity in Diabetic Macular Edema. JAMA Ophthalmology, 2018, 136, 1215.	1.4	40
58	Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial. American Journal of Ophthalmology, 2016, 170, 206-213.	1.7	39
59	COVID-19, COVID-19 Vaccinations, and Subsequent Abnormalities in the Retina. JAMA Ophthalmology, 2021, 139, 1135.	1.4	39
60	Aphakic Cystoid Macular Edema. JAMA Ophthalmology, 1985, 103, 1134.	2.6	38
61	CHANGES IN DIABETIC RETINOPATHY SEVERITY WHEN TREATING DIABETIC MACULAR EDEMA WITH RANIBIZUMAB. Retina, 2018, 38, 1896-1904.	1.0	38
62	Multimodal Imaging in Persistent Placoid Maculopathy. JAMA Ophthalmology, 2014, 132, 38.	1.4	36
63	Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy. JAMA Ophthalmology, 2020, 138, 285.	1.4	35
64	Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. Ophthalmology, 2018, 125, 1054-1063.	2,5	32
65	Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy. JAMA Ophthalmology, 2019, 137, 1424.	1.4	32
66	Elimination of Topical Antibiotics for Intravitreous Injections and the Importance of Using Povidone-Iodine. JAMA Ophthalmology, 2016, 134, 1181.	1.4	31
67	Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. , 2018, 59, 1199.		31
68	Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. New England Journal of Medicine, 2022, 387, 692-703.	13.9	31
69	MULTIPLE SEROUS RETINAL DETACHMENTS AND SUBRETINAL DEPOSITS AS THE PRESENTING SIGNS OF METASTATIC MELANOMA. Retina, 2004, 24, 320-322.	1.0	30
70	Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity. JAMA Ophthalmology, 2020, 138, 341.	1.4	30
71	Evaluation of Results 1 Year Following Short-term Use of Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy. JAMA Ophthalmology, 2014, 132, 889.	1.4	29
72	Assessing the Effect of Personalized Diabetes Risk Assessments During Ophthalmologic Visits on Glycemic Control. JAMA Ophthalmology, 2015, 133, 888.	1.4	29

#	Article	IF	CITATIONS
73	Nonsteroidal Anti-inflammatory Drugs and Cataract Surgery. JAMA Ophthalmology, 1994, 112, 891.	2.6	27
74	Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy. Ophthalmology, 2018, 125, 1776-1783.	2.5	25
75	ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY. Retina, 2020, 40, 1021-1028.	1.0	21
76	CHARACTERIZING PHOTORECEPTOR CHANGES IN ACUTE POSTERIOR MULTIFOCAL PLACOID PIGMENT EPITHELIOPATHY USING ADAPTIVE OPTICS. Retina, 2018, 38, 39-48.	1.0	19
77	A case of recurrent, self-inflicted handheld laser retinopathy. Journal of AAPOS, 2016, 20, 168-170.	0.2	18
78	Peripapillary retinal splitting visualized on OCT in glaucoma and glaucoma suspect patients. PLoS ONE, 2017, 12, e0182816.	1.1	18
79	OCT Angiography Imaging in Serpiginous Choroidopathy. Ophthalmology Retina, 2018, 2, 351-359.	1.2	18
80	The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma. Ophthalmology, 2020, 127, S148-S157.	2.5	18
81	A Multiple Evanescent White Dot Syndrome–like Reaction to Concurrent Retinal Insults. Ophthalmology Retina, 2021, 5, 1017-1026.	1.2	18
82	Optical Coherence Tomography Angiography Quality Across Three Multicenter Clinical Studies of Diabetic Retinopathy. Translational Vision Science and Technology, 2021, 10, 2.	1.1	17
83	Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy. JAMA Ophthalmology, 2021, 139, 725-733.	1.4	16
84	Retinal toxicity found in a patient with systemic lupus erythematosus prior to 5 years of treatment with hydroxychloroquine. Rheumatology, 2014, 53, 2001-2001.	0.9	15
85	PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY. Retina, 2019, 39, 1646-1654.	1.0	15
86	CHARACTERIZATION AND CORRELATION OF "JAMPOL DOTS―ON ADAPTIVE OPTICS WITH FOVEAL GRANULARITY ON CONVENTIONAL FUNDUS IMAGING. Retina, 2019, 39, 235-246.	1.0	15
87	A Randomized Trial of Photobiomodulation Therapy for Center-Involved Diabetic Macular Edema with Good Visual Acuity (Protocol AE). Ophthalmology Retina, 2022, 6, 298-307.	1.2	15
88	Comparative Effectiveness Trial for Diabetic Macular Edema. JAMA Ophthalmology, 2015, 133, 983.	1.4	13
89	Need for a New Classification of Diabetic Retinopathy. Retina, 2021, 41, 459-460.	1.0	13
90	Ebola and the Eye. JAMA Ophthalmology, 2015, 133, 1105.	1.4	12

#	Article	IF	CITATIONS
91	Interim Safety Data Comparing Ranibizumab With Panretinal Photocoagulation Among Participants With Proliferative Diabetic Retinopathy. JAMA Ophthalmology, 2017, 135, 672.	1.4	12
92	Solitary retinal hemangioblastoma findings in OCTA pre- and post-laser therapy. American Journal of Ophthalmology Case Reports, 2018, 10, 59-61.	0.4	11
93	CLINICALLY INVISIBLE RETINAL HEMANGIOBLASTOMAS DETECTED BY SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY AND FLUORESCEIN ANGIOGRAPHY IN TWINS. Retinal Cases and Brief Reports, 2018, 12, 12-16.	0.3	11
94	Further studies of the ipsilateral and contralateral responses to topical nitrogen mustard. Experimental Eye Research, 1979, 28, 591-600.	1.2	10
95	Pneumatic Vitreolysis with Perfluoropropane for Vitreomacular Traction with and without Macular Hole. Ophthalmology, 2021, 128, 1592-1603.	2.5	10
96	Imaging of a Cilioretinal Artery Embolisation. International Journal of Molecular Sciences, 2014, 15, 15734-15740.	1.8	9
97	OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FEATURES OF FOCAL CHOROIDAL EXCAVATION AND THE CHOROIDAL STROMA VARIATIONS WITH OCCURRENCE OF EXCAVATION. Retina, 2020, 40, 2319-2324.	1.0	9
98	Report of the familial occurrence of systemic lupus erythematosus in male siblings. Arthritis and Rheumatism, 1973, 16, 221-224.	6.7	8
99	Multimodal Imaging and Choroidal Volumetric Changes After Half-fluence PDT in Central Serous Chorioretinopathy. Current Eye Research, 2016, 41, 97-106.	0.7	8
100	Classifications of diabetic macular edema. European Journal of Ophthalmology, 2020, 30, 6-7.	0.7	8
101	A Perspective on Commercial Relationships Between Ophthalmology and Industry. JAMA Ophthalmology, 2009, 127, 1194.	2.6	7
102	Reversible Nyctalopia and Retinopathy in a Patient With Metastatic Cancer Treated With Anti–Heat Shock Protein 90 Therapy. JAMA Ophthalmology, 2014, 132, 899.	1.4	7
103	PANRETINAL PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY. Retina, 2019, 39, 69-78.	1.0	7
104	Diffuse Uveal Melanocytic Proliferation With Primary Vitreoretinal Lymphoma. JAMA Ophthalmology, 2019, 137, 834.	1.4	6
105	Best Vitelliform Macular Dystrophy (BVMD) is a phenocopy of North Carolina Macular Dystrophy (NCMD/MCDR1). Ophthalmic Genetics, 2021, , 1-11.	0.5	6
106	UNUSUAL SEROUS RETINAL DETACHMENT IN A PATIENT WITH WALDENSTROM MACROGLOBULINEMIA: A CASE REPORT. Retinal Cases and Brief Reports, 2019, 13, 1-4.	0.3	5
107	Relapsing Pigment Epithelial Detachment in Central Serous Chorioretinopathy After Dilated Eye Examination. JAMA Ophthalmology, 2020, 138, 1106.	1.4	5
108	INDOLENT, NONPROGRESSIVE, MULTIFOCAL CHOROIDAL LESIONS. Retina, 2020, 40, 1980-1987.	1.0	4

#	Article	IF	CITATIONS
109	CYSTOID MACULAR EDEMA IN THE SETTING OF PRIMARY VITREORETINAL LYMPHOMA. Retinal Cases and Brief Reports, 2021, 15, 104-106.	0.3	4
110	Acute Zonal Occult Outer Retinopathy (AZOOR). Retinal Cases and Brief Reports, 2020, Publish Ahead of Print, .	0.3	4
111	PARACENTRAL ACUTE MIDDLE MACULOPATHY IN CENTRAL RETINAL VEIN OCCLUSION COMPLICATING AMYLOID LIGHT-CHAIN AMYLOIDOSIS. Retinal Cases and Brief Reports, 2022, 16, 543-546.	0.3	4
112	Enhanced depth imaging optical coherence tomography of congenital cavitary optic disc anomaly (CODA). British Journal of Ophthalmology, 2015, 99, 549-555.	2.1	3
113	The Spectrum of Internal Limiting Membrane Disease in Alport Syndrome. Retina, 2021, Publish Ahead of Print, .	1.0	3
114	MMP19 expression in the human optic nerve. Molecular Vision, 2016, 22, 1429-1436.	1.1	3
115	Characterization of Choriocapillaris and Choroidal Abnormalities in Alport Syndrome. Translational Vision Science and Technology, 2022, 11, 23.	1.1	3
116	Zika Virus, Microcephaly, and Ocular Findings—Reply. JAMA Ophthalmology, 2016, 134, 946.	1.4	2
117	Keeping the Name of Acute Posterior Multifocal Placoid Pigment Epitheliopathy. JAMA Ophthalmology, 2017, 135, 186.	1.4	2
118	Photocoagulation of Transudative Type 2 Retinal Arteriovenous Malformation. JAMA Ophthalmology, 2021, 139, 805.	1.4	2
119	Managing Center-Involved Diabetic Macular Edema With Good Visual Acuity. JAMA Ophthalmology, 2022, 140, 95.	1.4	2
120	Prevention of Hydroxychloroquine-Related Retinal Toxic Effects—Reply. JAMA Ophthalmology, 2015, 133, 492.	1.4	1
121	Reply. Ophthalmology, 2017, 124, e26-e27.	2.5	1
122	Association of Retinal Macrovessels With Venous Malformations of the Brain. JAMA Ophthalmology, 2018, 136, 380.	1.4	1
123	Diffuse Uveal Melanocytic Proliferation With Primary Vitreoretinal Lymphoma—Reply. JAMA Ophthalmology, 2019, 137, 1466.	1.4	1
124	SEGMENTAL DIFFUSE VASCULAR LEAKAGE. Retinal Cases and Brief Reports, 2019, Publish Ahead of Print, 628-631.	0.3	1
125	Optic nerve head reactive retinal astrocytic tumor treated with photodynamic therapy. American Journal of Ophthalmology Case Reports, 2020, 19, 100827.	0.4	1
126	Indolent Nonprogressive Multifocal Choroidal Lymphoid Lesions. Ophthalmology Retina, 2022, 6, 957-962.	1.2	1

#	Article	IF	CITATIONS
127	Spotlight on the DRCR Retina Network's Photobiomodulation for Diabetic Macular Edema Trial. JAMA Ophthalmology, 2022, , .	1.4	1
128	TRIBUTE TO YANNUZZI. Retina, 2012, 32, S19-S20.	1.0	0
129	Melvin L. Rubin, MD (1932-2014). JAMA Ophthalmology, 2014, 132, 788.	1.4	0
130	Reply. Retina, 2015, 35, e68-e69.	1.0	0
131	Reply. Ophthalmology, 2017, 124, e5-e6.	2.5	0
132	Reply. Ophthalmology, 2017, 124, e38-e39.	2.5	0
133	Reply. Ophthalmology, 2018, 125, e82.	2.5	0
134	The Role of Optical Coherence Tomography Angiography in Ranibizumab-Treated Choroidal Neovascularization in Choroidal Osteoma. Case Reports in Ophthalmology, 2020, 11, 370-376.	0.3	0